soft tissue sarcoma
Conditions
Interventions
experimental group:Individualized second-line therapy based on minipdx / FGI Technology
control group:Conventional second-line treatment
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients voluntarily participated in the study, signed the informed consent, and had good compliance and cooperated with the follow-up; 2. The final pathological type was confirmed by pathology department of Shanghai Sixth People's hospital; 3. There is no indication of surgical treatment for the target lesion or the patient refuses to operate; 4. Patients who have used at least one first-line regimen for treatment failure or intolerance in the last 6 months; 5. Aged 18-70 years; 6. ECoG PS score: = 80g / L; 2) The absolute value of neutrophil (ANC) >=1.5 x 10^9 / L; 3) Platelet (PLT) >= 80 x 109 / L. (2) Biochemical examination should meet the following standards: 1) Total bilirubin (TBIL) = 60 ml / min. 9. Women of childbearing age should agree that contraceptive measures (such as intrauterine device, contraceptive or condom) must be used during the study period and within 6 months after the end of the study; serum or urine pregnancy test negative within 7 days before study enrollment, and must be non lactating patients; men should agree that contraceptive measures must be used during the study period and within 6 months after the end of the study period.
Exclusion criteria
Exclusion criteria: 1. Patients with hypertension, who can not keep stable after regular blood pressure lowering therapy, have coronary heart disease (CHD) of grade II, arrhythmia (including QTc interval prolongation, male > 450 ms, female > 470 MS) and cardiac dysfunction; 2. Abnormal coagulation function (INR > 1.5 x ULN, APTT > 1.5 x ULN) with bleeding tendency; 3. Active bleeding within 30 days after major operation; 4. Intracranial metastasis; 5. Pregnant or lactating women; 6. Other malignant tumors in the past three years; 7. The researcher believes that there is any condition that may damage the subject or cause the subject to be unable to meet or perform the research requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, OS;Objective Response Rate, ORR;Duration of Response, DOR;Disease Control Rate, DCR; | — |
Countries
China
Contacts
Public ContactShen Zan
Shanghai Sixth People's Hospital
Outcome results
None listed